Peptide
    Prescription Required

    PT-141

    Restore Desire & Performance Naturally

    A melanocortin receptor agonist that enhances libido and sexual function in both men and women through central nervous system activation.

    Enhanced libidoImproved sexual functionWorks for both sexesNon-hormonal

    About PT-141

    PT-141 (Bremelanotide) is a synthetic peptide originally developed from Melanotan II. Unlike traditional sexual dysfunction treatments that work on the vascular system, PT-141 works directly on the nervous system to enhance sexual desire and arousal. It's FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women and is used off-label for male sexual dysfunction. PT-141 is unique because it addresses desire, not just physical function—making it effective for both psychological and physiological aspects of sexual health.

    Mechanism of Action

    PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, the brain region that controls sexual arousal. This central mechanism means it works on desire and arousal at their source, rather than simply increasing blood flow. The result is genuine sexual interest and improved response, not just mechanical function.

    How PT-141 Works in Your Body:

    • Target Receptors: PT-141 binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
    • Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
    • Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.

    Dosing Protocol

    Frequency

    As needed, 45-60 minutes before activity

    Timing

    Not more than once in 24 hours, max 8 times per month

    Duration

    Use as needed

    Important Notes

    1.75mg subcutaneous injection. Effects can last 6-72 hours. Do not use with alcohol.

    Clinical Research

    3 studies on PT-141

    Study #01

    Female HSDD Trial

    PT-141 showed statistically significant improvement in sexual desire and reduction in distress.

    Journal of Sexual Medicine

    Study #02

    Male Erectile Dysfunction

    70% of men with ED unresponsive to Viagra showed improvement with PT-141.

    Urology

    Study #03

    Mechanism Study

    Confirmed central nervous system activation via melanocortin pathway, distinct from PDE5 inhibitors.

    Annals of the New York Academy of Sciences

    Clinical Deep Dive

    PT-141 in Practice

    Evidence: Tier 1 (Meta-analyses / RCTs)Last reviewed: 2026-04-22

    Who PT-141 is for

    Premenopausal women with hypoactive sexual desire disorder (HSDD) who want a non-hormonal option, and men with erectile dysfunction unresponsive to PDE5 inhibitors (sildenafil, tadalafil). PT-141 works on desire at the brain level, so it's particularly suited to people whose dysfunction has a psychological or neurological component rather than a purely vascular one.

    Who should avoid it

    Anyone with uncontrolled hypertension, cardiovascular disease, or a history of stroke. PT-141 transiently raises blood pressure (typically 6 mmHg systolic) and lowers heart rate. It is also not recommended for use with alcohol, which amplifies the nausea and orthostatic effects. Avoid in pregnancy.

    Clinical Context

    PT-141 (bremelanotide) was FDA-approved as Vyleesi in 2019 for premenopausal HSDD, making it one of the few peptides with a full FDA pathway. The pivotal RECONNECT trials enrolled over 1,200 women across two 24-week studies. About 25% of women on PT-141 reported meaningful improvement in desire vs 17% on placebo. The drug is administered as a single 1.75 mg subcutaneous autoinjector dose at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and a maximum of eight doses per month to limit hyperpigmentation risk from chronic melanocortin activation.

    Common Mistakes to Avoid

    Using it daily

    PT-141 is an as-needed medication, not a daily protocol. Daily dosing risks tachyphylaxis (diminished response) and accelerates hyperpigmentation. Stick to the maximum of 8 doses per month.

    Combining with alcohol

    Alcohol significantly increases nausea, the most common side effect. Wait at least 2 hours after drinking before dosing — and even then, expect a worse experience.

    Expecting an erection drug

    PT-141 is not a vasodilator. It enhances desire and arousal centrally. If your issue is purely vascular (failure to maintain), a PDE5 inhibitor is more appropriate. PT-141 shines for libido and central arousal.

    Dosing too late

    Effects peak 2-6 hours after injection. Most users get the best results dosing 60-90 minutes before activity, not 15 minutes before.

    Potential Side Effects

    • Nausea (most common, usually mild)
    • Flushing
    • Headache
    • Nasal congestion

    Stacks Well With

    Combining peptides can create synergistic effects. Learn about optimal timing, dosing, and protocols.

    Learn More About PT-141

    Explore our research library and educational resources to understand how PT-141 can support your health goals.